1165 related articles for article (PubMed ID: 30514362)
1. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.
Henke G; Knauer M; Ribi K; Hayoz S; Gérard MA; Ruhstaller T; Zwahlen DR; Muenst S; Ackerknecht M; Hawle H; Fitzal F; Gnant M; Mátrai Z; Ballardini B; Gyr A; Kurzeder C; Weber WP
Trials; 2018 Dec; 19(1):667. PubMed ID: 30514362
[TBL] [Abstract][Full Text] [Related]
2. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.
Krag DN; Anderson SJ; Julian TB; Brown AM; Harlow SP; Costantino JP; Ashikaga T; Weaver DL; Mamounas EP; Jalovec LM; Frazier TG; Noyes RD; Robidoux A; Scarth HM; Wolmark N
Lancet Oncol; 2010 Oct; 11(10):927-33. PubMed ID: 20863759
[TBL] [Abstract][Full Text] [Related]
3. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
4. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
[TBL] [Abstract][Full Text] [Related]
5. Management of the Axilla in T1-2 Breast Cancer Patients with Macrometastatic Sentinel Node Involvement Who Underwent Breast-Conserving Therapy.
Kuru B; Yuruker S; Sullu Y; Gursel B; Ozen N
J Invest Surg; 2019 Jan; 32(1):48-54. PubMed ID: 28945489
[TBL] [Abstract][Full Text] [Related]
6. Tailored axillary surgery - A novel concept for clinically node positive breast cancer.
Heidinger M; Knauer M; Tausch C; Weber WP
Breast; 2023 Jun; 69():281-289. PubMed ID: 36922305
[TBL] [Abstract][Full Text] [Related]
7. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
[TBL] [Abstract][Full Text] [Related]
8. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
Giuliano AE; Hunt KK; Ballman KV; Beitsch PD; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; McCall LM; Morrow M
JAMA; 2011 Feb; 305(6):569-75. PubMed ID: 21304082
[TBL] [Abstract][Full Text] [Related]
9. Personalized axillary dissection: the number of excised lymph nodes of nodal-positive breast cancer patients has no significant impact on relapse-free and overall survival.
Ebner F; Wöckel A; Janni W; Kreienberg R; Schwentner L; Wischnewsky M
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1823-1831. PubMed ID: 28439713
[TBL] [Abstract][Full Text] [Related]
10. Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
Weber WP; Heidinger M; Hayoz S; Matrai Z; Tausch C; Henke G; Zwahlen DR; Gruber G; Zimmermann F; Montagna G; Andreozzi M; Goldschmidt M; Schulz A; Mueller A; Ackerknecht M; Tampaki EC; Bjelic-Radisic V; Kurzeder C; Sávolt Á; Smanykó V; Hagen D; Müller DJ; Gnant M; Loibl S; Fitzal F; Markellou P; Bekes I; Egle D; Heil J; Knauer M
Ann Surg Oncol; 2024 Jan; 31(1):344-355. PubMed ID: 37903951
[TBL] [Abstract][Full Text] [Related]
11. Axillary lymph node treatment in breast cancer: an update.
Williams PA; Suggs J; Mangana SH
J Miss State Med Assoc; 2014 May; 55(5):145-7. PubMed ID: 25112128
[TBL] [Abstract][Full Text] [Related]
12. Is regional nodes radiotherapy an alternative to surgery?
Offersen BV; Nielsen HM; Overgaard M; Overgaard J
Breast; 2013 Aug; 22 Suppl 2():S118-28. PubMed ID: 24074772
[TBL] [Abstract][Full Text] [Related]
13. Axillary treatment for operable primary breast cancer.
Bromham N; Schmidt-Hansen M; Astin M; Hasler E; Reed MW
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004561. PubMed ID: 28052186
[TBL] [Abstract][Full Text] [Related]
14. [Management of the axilla in breast cancer: evidences and unresolved issues].
Fodor J; Polgár C; Péley G; Németh G
Orv Hetil; 2001 Sep; 142(36):1941-50. PubMed ID: 11680099
[TBL] [Abstract][Full Text] [Related]
15. Trends in axillary treatment for breast cancer patients undergoing sentinel lymph node biopsy as determined by a questionnaire from the Japanese Breast Cancer Society.
Imoto S; Yamauchi C; Komoike Y; Tsugawa K; Yotsumoto D; Wada N; Ueno T; Oba MS; Shien T; Sugae S; Tsuda H; Yoneyama K
Breast Cancer; 2017 May; 24(3):427-432. PubMed ID: 27553957
[TBL] [Abstract][Full Text] [Related]
16. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial.
de Boniface J; Frisell J; Andersson Y; Bergkvist L; Ahlgren J; Rydén L; Olofsson Bagge R; Sund M; Johansson H; Lundstedt D;
BMC Cancer; 2017 May; 17(1):379. PubMed ID: 28549453
[TBL] [Abstract][Full Text] [Related]
17. Radiation field design and regional control in sentinel lymph node-positive breast cancer patients with omission of axillary dissection.
Setton J; Cody H; Tan L; Morrow M; Hudis C; Catalano J; McCormick B; Powell S; Ho A
Cancer; 2012 Apr; 118(8):1994-2003. PubMed ID: 21882186
[TBL] [Abstract][Full Text] [Related]
18. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
[TBL] [Abstract][Full Text] [Related]
19. Will we need lymph node dissection at all in the future?
Bourez RL; Rutgers EJ; Van De Velde CJ
Clin Breast Cancer; 2002 Dec; 3(5):315-22; discussion 323-5. PubMed ID: 12533260
[TBL] [Abstract][Full Text] [Related]
20. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.
Galimberti V; Cole BF; Viale G; Veronesi P; Vicini E; Intra M; Mazzarol G; Massarut S; Zgajnar J; Taffurelli M; Littlejohn D; Knauer M; Tondini C; Di Leo A; Colleoni M; Regan MM; Coates AS; Gelber RD; Goldhirsch A;
Lancet Oncol; 2018 Oct; 19(10):1385-1393. PubMed ID: 30196031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
